Fish oil supplements in patients with chronic kidney disease
Clicks: 2
ID: 315110
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #98 of 128 articles by views in clinical kidney journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 128 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Cardiovascular disease (CVD) accounts for most of the increased morbidity and mortality associated with in chronic kidney disease (CKD). Cardiovascular risk emerges early in CKD, initially driven by atherosclerotic events but later dominated by heart failure and sudden cardiac death. This transition reflects progressive arteriosclerosis and the development of CKD-associated cardiomyopathy. Although patients receiving dialysis experience the highest cardiovascular risk, established atherosclerotic therapies such as lipid-lowering agents offer limited benefit at this stage. Recent therapeutic advances, including SGLT2 inhibitors, GLP1 receptor agonists and mineralocorticoid receptor antagonists, have improved outcomes in non-dialysis CKD, but the high cardiovascular mortality of dialysis patients remains largely unchanged, with multiple interventions having failed to demonstrate benefit. In this review, we outline the pleiotropic actions of omega-3 polyunsaturated fatty acids (PUFA) including anti-inflammatory, anti-oxidative, anti-thrombotic, plaque stabilising and membrane modulating effects. We discuss the PISCES trial that reported large reductions in cardiovascular events with high dose fish oil supplementation (1.6 g EPA + 0.8 g DHA daily) in 1 228 haemodialysis patients followed up for 3.5 years. This treatment lowered events comprising the primary endpoint by 43% with similar reductions observed in cardiac death, myocardial infarction and stroke. Prior studies of fish oils in CKD have been small and inconclusive, underscoring the need for further large, randomised trials to confirm efficacy. If validated, omega-3 PUFA therapy could represent a long-needed advance for improving cardiovascular outcomes in haemodialysis patients.
| Reference Key |
openalex_W7162520248
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Charles J. Ferro, Mark R Thomas, Sophia Khattak, Dimitrios Chanouzas, Jonathan N. TOWNEND |
| Journal | clinical kidney journal |
| Year | 2026 |
| DOI |
10.1093/ckj/sfag168
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.